Cytosorbents Corporation (NASDAQCM:CTSO) has seen its average one-year price target revised to $48.45 per share, reflecting a significant increase of 1,900% from the previous estimate of $2.42, dated August 25, 2026. This target represents an average of various analyst projections collected by Fintel and indicates a potential rise of 698.20% from the recent closing price of $6.07 as of September 14, 2026.
Historically, the average target for Cytosorbents was recorded at $2.93 on August 4, 2026, indicating a target change of +1,552.17% since June 8, 2026. In its latest earnings report on August 6, 2026, the company reported a revenue of $9,633,000, surpassing estimates by 1.05%, while actual earnings per share (EPS) were -0.07 against an estimate of -0.0459.
Currently, the analyst recommendation trend reflects three hold ratings, one sell rating, and two strong sell ratings, unchanged since August 1, 2026. The company is classified within the biotechnology sector, focusing on critical care immunotherapy products, notably its blood purification technology, CytoSorb.
5 Stocks Our Experts Predict Could Double In the Next Year
By submitting your email, you'll also get a free pivot & flow membership. A free daily market overview. You can unsubscribe at any time.
